Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
about
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
P2860
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Development of a versatile onc ...... ion of therapeutic transgenes.
@ast
Development of a versatile onc ...... ion of therapeutic transgenes.
@en
type
label
Development of a versatile onc ...... ion of therapeutic transgenes.
@ast
Development of a versatile onc ...... ion of therapeutic transgenes.
@en
prefLabel
Development of a versatile onc ...... ion of therapeutic transgenes.
@ast
Development of a versatile onc ...... ion of therapeutic transgenes.
@en
P2093
P2860
P1433
P1476
Development of a versatile onc ...... sion of therapeutic transgenes
@en
P2093
Ashvin Patel
Brian R Champion
Hugo Calderon
Kerry D Fisher
Nalini Marino
Prithvi Kodialbail
Rochelle Lear
Sam Illingworth
P2860
P304
P356
10.1371/JOURNAL.PONE.0177810
P407
P577
2017-05-18T00:00:00Z